Related Experiment Video
Updated: Feb 5, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
[Thrombosis in multiple myeloma]
1Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Science.
Abstract:
Reportedly, patients with cancer have an increased risk (four- to seven-fold) of developing thrombotic events (TEs) compared with healthy volunteers. Multiple myeloma (MM) is one of the neoplasms that exhibit a high incidence of TEs, and approximately 10% patients with MM develop TEs during their clinical courses. The underlying risk factors of TEs are classified into patient-, disease-, and treatment-related factors. Specific treatment-related risk factors comprise the use of immunomodulatory drugs combined with dexamethasone. As the occurrence of TE in patients hampers the treatment for MM itself, which results in unfavorable outcomes, elucidating TE pathogenesis and adequate prophylaxis for each patient are essential to prevent MM-related TEs.
Related Concept Videos
Venous Thrombosis I: Introduction
Multiple Allele Traits
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Multiple Regression
Farmers can use multiple regression to determine the crop yield based on more than one factor, such as water availability, fertilizer, soil properties, etc. Here, the crop yield is the response or dependent variable as it depends on the other independent variables. The analysis requires the construction of a scatter plot...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

